[go: up one dir, main page]

NO884771D0 - Fremgangsmaate for fremstilling av et kimerisk antistoffmolekyl. - Google Patents

Fremgangsmaate for fremstilling av et kimerisk antistoffmolekyl.

Info

Publication number
NO884771D0
NO884771D0 NO884771A NO884771A NO884771D0 NO 884771 D0 NO884771 D0 NO 884771D0 NO 884771 A NO884771 A NO 884771A NO 884771 A NO884771 A NO 884771A NO 884771 D0 NO884771 D0 NO 884771D0
Authority
NO
Norway
Prior art keywords
procedure
preparation
antibody molecule
chemical antibody
chemical
Prior art date
Application number
NO884771A
Other languages
English (en)
Other versions
NO178234C (no
NO178234B (no
NO884771L (no
Inventor
Kim R Folger Bruce
Henry Perry Fell Jr
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of NO884771D0 publication Critical patent/NO884771D0/no
Publication of NO884771L publication Critical patent/NO884771L/no
Priority to NO952051A priority Critical patent/NO952051D0/no
Publication of NO178234B publication Critical patent/NO178234B/no
Publication of NO178234C publication Critical patent/NO178234C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
NO884771A 1987-10-27 1988-10-26 Fremgangsmåte for fremstilling av et kimærisk antistoffmolekyl NO178234C (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO952051A NO952051D0 (no) 1987-10-27 1995-05-23 Fremgangsmåte for fremstilling av et kimærisk antistoffmolekyl

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11380087A 1987-10-27 1987-10-27
US07/243,873 US5204244A (en) 1987-10-27 1988-09-14 Production of chimeric antibodies by homologous recombination

Publications (4)

Publication Number Publication Date
NO884771D0 true NO884771D0 (no) 1988-10-26
NO884771L NO884771L (no) 1989-04-28
NO178234B NO178234B (no) 1995-11-06
NO178234C NO178234C (no) 1996-02-14

Family

ID=26811495

Family Applications (1)

Application Number Title Priority Date Filing Date
NO884771A NO178234C (no) 1987-10-27 1988-10-26 Fremgangsmåte for fremstilling av et kimærisk antistoffmolekyl

Country Status (17)

Country Link
US (1) US5204244A (no)
EP (1) EP0315062B1 (no)
JP (1) JP2624314B2 (no)
CN (1) CN1033290A (no)
AU (1) AU607013B2 (no)
CA (1) CA1334177C (no)
CY (1) CY1778A (no)
DE (1) DE3887085T2 (no)
DK (1) DK174339B1 (no)
ES (1) ES2061598T3 (no)
FI (1) FI97303C (no)
HK (1) HK63094A (no)
IE (1) IE61733B1 (no)
IL (1) IL88149A (no)
NO (1) NO178234C (no)
NZ (1) NZ226695A (no)
PT (1) PT88858B (no)

Families Citing this family (391)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
ATE140963T1 (de) * 1988-01-22 1996-08-15 Zymogenetics Inc Verfahren zur herstellung von sekretierten rezeptoranalogen
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
EP0345466A3 (en) * 1988-05-10 1991-04-17 EASTMAN KODAK COMPANY (a New Jersey corporation) Generation of chimeric antibodies in vivo by site-specific recombination
EP0397834B1 (en) 1988-10-28 2000-02-02 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US6780613B1 (en) * 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
ATE236249T1 (de) 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
CA2066720A1 (en) * 1989-09-19 1991-03-20 David M. Knight Method for improving human monoclonal antibody production
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (en) * 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5877397A (en) * 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) * 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7084260B1 (en) * 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) * 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) * 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US7405270B2 (en) 1991-10-25 2008-07-29 Immunex Corporation CD40-Ligand lacking native-pattern glycosylation
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5961974A (en) 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
EP0867511A1 (en) * 1992-03-10 1998-09-30 La Jolla Cancer Research Foundation Recombinant calf intestinal alkaline phosphatase
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
KR100463476B1 (ko) * 1993-12-23 2005-07-01 머크 앤드 캄파니 인코포레이티드 쥐과의동물세포들을위한상동성재조합항체발현시스템
HU221513B (en) 1993-12-23 2002-10-28 Merck & Co Inc Homologous recombination antibody expression system
EP0742830B1 (en) 1994-02-01 2001-07-18 THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services Fusion proteins that include antibody and nonantibody portions
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
EP0823941A4 (en) * 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
CZ299025B6 (cs) 1996-02-09 2008-04-02 Amgen Inc. Farmaceutická kompozice a její použití
ES2384942T3 (es) * 1996-12-03 2012-07-16 Amgen Fremont Inc. Anticuerpos humanos que se unen específicamente al TNF alfa
CA2273852C (en) 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
DK0966533T3 (da) 1997-02-07 2010-01-04 Us Gov Health & Human Serv Aktivitetsafhængig neurotrof faktor III (ADNF III).
ATE501170T1 (de) 1997-04-07 2011-03-15 Genentech Inc Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese
DK0973804T3 (da) 1997-04-07 2007-05-07 Genentech Inc Anti-VEGF-antistoffer
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
US6391547B1 (en) * 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
NZ520579A (en) * 1997-10-24 2004-08-27 Invitrogen Corp Recombinational cloning using nucleic acids having recombination sites and methods for synthesizing double stranded nucleic acids
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1141024B1 (en) * 1999-01-15 2018-08-08 Genentech, Inc. POLYPEPTIDE COMPRISING A VARIANT HUMAN IgG1 Fc REGION
US6864235B1 (en) * 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6911429B2 (en) * 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
EP1292619B1 (en) 2000-06-06 2008-02-06 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
MXPA03001915A (es) * 2000-08-03 2004-09-10 Therapeutic Human Polyclonals Produccion de anticuerpos humanizados en animales transgenicos.
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7476536B2 (en) * 2001-05-11 2009-01-13 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody a light chain gene
NZ532526A (en) * 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
EP1451323A2 (en) * 2001-11-09 2004-09-01 Transition Therapeutics Inc. Pharmaceutical compositions of marine sponge microciona prolifera
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
EP1572121B1 (en) 2002-08-01 2012-01-11 The Regents of The University of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
ES2373947T3 (es) * 2002-12-16 2012-02-10 Genmab A/S Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
US7932242B2 (en) 2004-03-16 2011-04-26 Temple University - Of The Commonwealth System Of Higher Education Substituted phenoxy-and phenylthio-derivatives for treating proliferative disorders
WO2005095458A1 (en) * 2004-04-02 2005-10-13 The Talwar Research Foundation CHIMERIC MONOCLONAL ANTIBODY FOR BINDING WITH HIGH AFFINITY SELECTIVELY TO hCG
US7794713B2 (en) 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP4633788B2 (ja) 2004-04-13 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー 抗ｐ−セレクチン抗体
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
BRPI0516011A (pt) 2004-09-24 2008-08-19 Amgen Inc moléculas fc modificadas
CN101107007B (zh) 2005-01-27 2011-08-17 奥克兰儿童医院及研究中心 对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
JP2008528060A (ja) 2005-01-27 2008-07-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ボツリヌス神経毒素を中和する治療的モノクローナル抗体
TW200720289A (en) * 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007019865A2 (en) * 2005-08-18 2007-02-22 Genmab A/S Therapy with cd4 binding peptides and radiation
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
WO2007117410A2 (en) * 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
US20080014203A1 (en) * 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
JP2010500984A (ja) 2006-08-17 2010-01-14 エフ．ホフマン−ラ ロシュ アーゲー Ｃｃｒ５に対する抗体と抗膜融合ペプチドとの抱合体
TW200817438A (en) * 2006-08-17 2008-04-16 Hoffmann La Roche A conjugate of an antibody against CCR5 and an antifusogenic peptide
CN102719444B (zh) 2006-09-01 2016-12-14 人类多细胞株治疗学公司 人或人源化免疫球蛋白在非人转基因动物中增强的表达
ATE550355T1 (de) 2006-09-29 2012-04-15 Hoffmann La Roche Antikörper gegen ccr5 und ihre verwendung
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
DK2087002T3 (da) * 2006-10-27 2014-10-27 Lpath Inc Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
US8444970B2 (en) * 2006-10-27 2013-05-21 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
US20080226635A1 (en) * 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
ES2585702T3 (es) * 2007-05-30 2016-10-07 Lpath, Inc Composiciones y métodos para la unión al ácido lisofosfatídico
HUE037060T2 (hu) * 2007-06-29 2018-08-28 Hoffmann La Roche Javított immunglobulin-termeléshez vezetõ nehézlánc-mutáns
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
EP2197918B1 (en) 2007-09-05 2013-12-18 F. Hoffmann-La Roche AG Combination therapy with type i and type ii anti-cd20 antibodies
EP2192922A4 (en) 2007-09-17 2010-09-29 Univ California INTERNATIONALIZING HUMAN MONOCLONAL ANTIBODIES TO PROMOTE IN SITU ON PROSTATAZELLES
AU2008309934B2 (en) 2007-10-12 2014-03-06 F. Hoffmann-La Roche Ag Protein expression from multiple nucleic acids
US20090098118A1 (en) 2007-10-15 2009-04-16 Thomas Friess Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
CN101896820A (zh) * 2007-12-15 2010-11-24 霍夫曼-拉罗奇有限公司 区分测定
US8227577B2 (en) * 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2009083246A1 (en) 2007-12-31 2009-07-09 Bayer Schering Pharma Aktiengesellschaft Antibodies to tnf alpha
DK2238170T3 (en) 2008-01-31 2017-02-27 Inserm - Inst Nat De La Santé Et De La Rech Médicale ANTIBODIES AGAINST HUMAN CD39 AND ITS USE FOR INHIBITING ACTIVITY OF T-REGULATORY CELLS
DK2279004T3 (en) 2008-05-16 2015-02-02 Hoffmann La Roche USE OF biomarkers for assessment of treatment of gastrointestinal inflammatory disorders WITH beta7 integrin antagonists
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
WO2010040766A1 (en) 2008-10-07 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
US8268314B2 (en) * 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
EP2398913B1 (en) 2009-02-20 2016-03-30 F. Hoffmann-La Roche AG Method for obtaining immunoglobulin encoding nucleic acid
WO2010106051A1 (en) 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
CN102361632A (zh) 2009-03-30 2012-02-22 弗·哈夫曼-拉罗切有限公司 避免玻璃雾化的方法
AR075982A1 (es) 2009-03-31 2011-05-11 Roche Glycart Ag Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion
EP2236139A1 (en) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
WO2010112194A1 (en) 2009-04-02 2010-10-07 F. Hoffmann-La Roche Ag Antigen-binding polypeptides and multispecific antibodies comprising them
RU2598248C2 (ru) 2009-04-02 2016-09-20 Роше Гликарт Аг Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
WO2010115552A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
SI2417156T1 (sl) 2009-04-07 2015-06-30 Roche Glycart Ag Trivalentna, bispecifiäśna protitelesa
KR20110124368A (ko) 2009-04-07 2011-11-16 로슈 글리카트 아게 이중특이적 항―ｅｒｂｂ―２／항―ｃ―ｍｅｔ 항체
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP5758888B2 (ja) 2009-07-06 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性ジゴキシゲニン結合抗体
ES2538819T3 (es) 2009-07-30 2015-06-24 F. Hoffmann-La Roche Ag Procesamiento enzimático de anticuerpos
AU2010280847B2 (en) 2009-08-04 2012-12-13 F. Hoffmann-La Roche Ag Beta cell marker antibody
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
US20110053223A1 (en) 2009-08-14 2011-03-03 Robert Bayer Cell culture methods to make antibodies with enhanced adcc function
JP2013501741A (ja) 2009-08-14 2013-01-17 ロシュ グリクアート アーゲー アフコシル化ｃｄ２０抗体とフルダラビン及び／又はミトキサントロンの併用療法
TWI409079B (zh) 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化ｃｄ２０抗體與苯達莫斯汀（ｂｅｎｄａｍｕｓｔｉｎｅ）之組合療法
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
EP2289542A1 (en) 2009-08-31 2011-03-02 PAION Deutschland GmbH Treatment of neurological or neurodegenerative disorders
WO2011026640A1 (en) 2009-09-07 2011-03-10 F. Hoffmann-La Roche Ag Es-ms of glycopeptides for analysis of glycosylation
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
NZ598962A (en) 2009-09-16 2014-12-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
AU2010303142B2 (en) 2009-09-29 2013-05-09 Roche Glycart Ag Bispecific death receptor agonistic antibodies
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
SG2014014823A (en) 2009-10-19 2014-07-30 Hoffmann La Roche Non-cross-reactive anti igg antibodies
ES2981683T3 (es) 2009-10-26 2024-10-10 Hoffmann La Roche Procedimiento para la producción de una inmunoglobulina glucosilada
WO2011064179A1 (en) 2009-11-26 2011-06-03 F. Hoffmann-La Roche Ag Marker protein for type 2 diabetes
SI2949670T1 (sl) 2009-12-10 2019-05-31 F. Hoffmann-La Roche Ag Protitelesa, ki se preferenčno vežejo na zunajcelično domeno 4 človeškega CSF1R, in njihova uporaba
AU2010335282B2 (en) 2009-12-22 2015-05-21 Roche Glycart Ag Anti-HER3 antibodies and uses thereof
EP2516460B1 (en) 2009-12-22 2015-03-04 F.Hoffmann-La Roche Ag Sequence dependent aggregation
ES2753216T3 (es) 2010-01-15 2020-04-07 Amgen K A Inc Formulación de anticuerpos anti-IL17RA y regímenes terapéuticos para el tratamiento de la psoriasis
US20120294866A1 (en) 2010-01-19 2012-11-22 F. Hoffmann-La Roche Ag Pharmaceutical formulation for proteins
WO2011101328A2 (en) 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
JP2013521765A (ja) 2010-03-05 2013-06-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
WO2011119549A1 (en) 2010-03-22 2011-09-29 President And Fellows Of Harvard College Trioxacarcins and uses thereof
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
DK2553100T3 (en) 2010-03-31 2017-10-23 Ablexis Llc REPLACING NON-HUMAN ANIMALS TO CREATE CHIMERARY ANTIBODIES
JP6042801B2 (ja) 2010-04-27 2016-12-14 ロシュ グリクアート アーゲー ｍＴＯＲインヒビターとのアフコシル化ＣＤ２０抗体の併用療法
EP2596025B1 (en) 2010-07-23 2018-06-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
RU2603284C2 (ru) 2010-08-17 2016-11-27 Ф.Хоффманн-Ля Рош Аг АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
TW201208703A (en) 2010-08-17 2012-03-01 Roche Glycart Ag Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
JP5758004B2 (ja) 2010-08-24 2015-08-05 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ジスルフィドによって安定化されたＦｖ断片を含む二重特異性抗体
WO2012027440A1 (en) 2010-08-24 2012-03-01 Abbott Laboratories Hiv core protein specific antibodies and uses thereof
SG188605A1 (en) 2010-10-05 2013-04-30 Hoffmann La Roche Antibodies against human tweak and uses thereof
DK2633289T3 (en) 2010-10-25 2016-06-06 Hoffmann La Roche USE OF SIGNAL enhancing compounds in electrochemiluminesce DETECTION
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
CA2819436A1 (en) 2010-12-16 2012-06-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
EP2655412B1 (en) 2010-12-21 2018-01-17 F. Hoffmann-La Roche AG Isoform enriched antibody preparation and method for obtaining it
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
KR101572338B1 (ko) 2011-02-28 2015-11-26 에프. 호프만-라 로슈 아게 1가 항원 결합 단백질
SI2686334T2 (sl) 2011-03-16 2020-10-30 F. Hoffmann-La Roche Ag Ionska izmenjevalna kromatografija z izboljšano selektivnostjo za ločevanje polipeptidnih monomerov, agregatov in fragmentov s spremembo mobilne faze
BR112013024574B1 (pt) 2011-03-29 2022-08-09 Roche Glycart Ag Anticorpo e uso do anticorpo
BR112013025045B1 (pt) 2011-03-31 2020-10-27 INSERM (Institut National de la Santé et de la Recherche Médicale) anticorpos direcionados contra icos e usos dos mesmos
EP3412309A1 (en) 2011-03-31 2018-12-12 F. Hoffmann-La Roche AG Methods of administering beta7 integrin antagonists
AR086250A1 (es) 2011-05-05 2013-11-27 Hoffmann La Roche Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
ES2643694T3 (es) 2011-05-19 2017-11-23 Inserm (Institut National De La Santé Et De La Recherche Medicale) Anticuerpos anti-HER3 humanos y sus usos
BR112013032233A2 (pt) 2011-06-15 2016-11-22 Hoffmann La Roche ligação de anticorpo ao polipeptídeo abca1
KR20140104945A (ko) 2011-06-22 2014-08-29 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-ａｘｌ 항체 및 그의 용도
EP2723376B1 (en) 2011-06-22 2018-12-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
EP2543678A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543679A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
EP2543677A1 (en) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
BR112014004166A2 (pt) 2011-08-23 2018-05-29 Roche Glycart Ag anticorpo biespecífico compreendendo pelo menos dois fragmentos fab, célula hospedeira procariótica ou eucariótica, metodo de produção de um anticorpo, imunoconjugado e invenção
KR101870555B1 (ko) 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
SG10201912955PA (en) 2011-09-19 2020-02-27 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
US20150024434A1 (en) 2011-09-21 2015-01-22 Hoffmann-La Roche Inc. METHOD FOR OBTAINING FAB FRAGMENTS FROM SINGLE ANTIBODY PRODUCING CELLS BY MULTIPLEXED CPR IN COMBINATION WITH TaqMan PROBES
EP2758435A1 (en) 2011-09-23 2014-07-30 Roche Glycart AG Bispecific anti-egfr/anti igf-1r antibodies
SG2014012470A (en) 2011-10-05 2014-06-27 Hoffmann La Roche Process for antibody g1 glycoform production
US20130302274A1 (en) 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
FR2984750B1 (fr) 2011-12-23 2014-01-10 Lfb Biotechnologies Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
EP2812357B1 (en) 2012-02-10 2020-11-04 F.Hoffmann-La Roche Ag Single-chain antibodies and other heteromultimers
CN104136460A (zh) 2012-02-29 2014-11-05 霍夫曼-拉罗奇有限公司 减少1->3读框移位的方法
KR20140135716A (ko) 2012-02-29 2014-11-26 에프. 호프만-라 로슈 아게 1→2 해독 프레임 이동의 감소 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
SG11201404481RA (en) 2012-03-08 2014-09-26 Hoffmann La Roche Abeta antibody formulation
AR090244A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Formulacion de anticuerpo anti-selectina p
MX2014011818A (es) 2012-04-05 2014-12-10 Hoffmann La Roche Anticuerpos biespecificos contra inductor debil de la apoptosis relacionado con el tnf (tweak) humana e il17 humana y usos de los mismos.
EP2666786A1 (en) 2012-05-21 2013-11-27 PAION Deutschland GmbH Immunotherapy for intracranial hemorrhage
EP2855531A1 (en) 2012-05-24 2015-04-08 F. Hoffmann-La Roche AG Multispecific antibodies
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
EP2864355B1 (en) 2012-06-25 2016-10-12 Orega Biotech Il-17 antagonist antibodies
CA2871880A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
EP2684896A1 (en) 2012-07-09 2014-01-15 International-Drug-Development-Biotech Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
SMT202100621T1 (it) 2012-07-13 2022-01-10 Roche Glycart Ag Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
ES2684552T3 (es) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
CN104768581A (zh) 2012-09-07 2015-07-08 吉宁特有限公司 II型抗CD20抗体与选择性Bcl-2抑制剂的组合治疗
AU2013326921C1 (en) 2012-10-05 2018-01-18 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
EP2727943A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Trispecific antibodies against human EGFR, HER2 and HER3
EP2727942A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Bispecific antibodies against human EGFR, HER2, and HER3
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
EP2733153A1 (en) 2012-11-15 2014-05-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the preparation of immunoconjugates and uses thereof
UA120247C2 (uk) 2012-11-20 2019-11-11 Санофі Антитіло до ceacam5 і його застосування
JP6408478B2 (ja) 2012-11-26 2018-10-17 プレジデント アンド フェローズ オブ ハーバード カレッジ トリオキサカルシン、トリオキサカルシン−抗体複合体、およびその用途
WO2014093417A1 (en) 2012-12-12 2014-06-19 University Of Virginia Patent Foundation Compositions and methods for regulating erythropoiesis
JP6461808B2 (ja) 2012-12-17 2019-01-30 ラボラトワール フランセ ドゥ フラクションマン エ デ バイオテクノロジーズＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ Ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ Ｅｔ Ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ 炎症および細菌感染症処置におけるモノクローナル抗体の使用
ES2871816T3 (es) 2012-12-27 2021-11-02 Sanofi Sa Anticuerpos anti-LAMP1 y conjugados anticuerpo-fármaco, y usos de los mismos
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP2953972B1 (en) 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP3495814A3 (en) 2013-03-27 2019-07-17 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
ES2658039T3 (es) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
WO2015014979A1 (en) 2013-08-01 2015-02-05 F. Hoffmann-La Roche Ag Tnfa-il-17 bispecific antibodies
EP2832854A1 (en) 2013-08-02 2015-02-04 F. Hoffmann-La Roche AG Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
RU2704228C2 (ru) 2013-11-07 2019-10-24 Инсерм (Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль) Неконкурентные в отношении нейрегулина аллостерические антитела против человеческого her3 и их применения
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
AU2015235986B2 (en) 2014-03-27 2020-12-03 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
KR102530900B1 (ko) 2014-03-31 2023-05-12 암젠 케이-에이, 인크. 손발톱 및 두피 건선의 치료 방법
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
ES2924393T3 (es) 2014-04-16 2022-10-06 Inst Nat Sante Rech Med Anticuerpos para la prevención o el tratamiento de episodios hemorrágicos
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
EP3172233B1 (en) 2014-07-22 2019-09-11 Sutro Biopharma, Inc. Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
JP6692343B2 (ja) 2014-08-01 2020-05-13 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 薬物としての使用のための抗ｃｄ４５ｒｃ抗体
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
US11952421B2 (en) 2014-10-09 2024-04-09 Bristol-Myers Squibb Company Bispecific antibodies against CD3EPSILON and ROR1
WO2016059220A1 (en) 2014-10-16 2016-04-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Tcr-activating agents for use in the treatment of t-all
RU2730668C2 (ru) 2014-11-19 2020-08-24 Аксон Ньюросайенс Се Гуманизированные тау-антитела при болезни альцгеймера
ES2984937T3 (es) 2014-11-20 2024-10-31 Hoffmann La Roche Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T y antagonistas de la unión al eje de PD-1
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3029068A1 (en) 2014-12-03 2016-06-08 EngMab AG Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
UA126269C2 (uk) 2015-01-23 2022-09-14 Санофі АНТИТІЛОПОДІБНИЙ ЗВ’ЯЗУВАЛЬНИЙ БІЛОК, ЯКИЙ СПЕЦИФІЧНО ЗВ’ЯЗУЄТЬСЯ З ПОЗАКЛІТИННИМ ДОМЕНОМ CD3<font face="Symbol">e</font> ЛЮДИНИ І З CD123<font face="Symbol">e</font>
CN107257693A (zh) 2015-02-26 2017-10-17 豪夫迈·罗氏有限公司 治疗Crohn病的整联蛋白β7拮抗剂和方法
EP3280455A1 (en) 2015-04-07 2018-02-14 INSERM - Institut National de la Santé et de la Recherche Médicale Non-invasive imaging of tumor pd-l1 expression
EP3091033A1 (en) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3 antibodies and uses thereof
WO2016207124A1 (en) 2015-06-25 2016-12-29 F. Hoffmann-La Roche Ag Cell based assay for determining antibody or ligand binding and function
AU2016282869B2 (en) 2015-06-26 2022-08-18 Sanofi Biotechnology SAS Monoclonal anti-IL-1RAcP antibodies
PT3319995T (pt) 2015-07-07 2019-06-14 H Hoffnabb La Roche Ag Terapêutica combinada de um conjugado anticorpo anti-her2-fármaco com um inibidor de bcl-2
WO2017005847A1 (en) 2015-07-07 2017-01-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity to myosin 18a and uses thereof
EP3328886B1 (en) 2015-07-29 2020-09-16 Allergan, Inc. Heavy chain only antibodies to ang-2
US10683369B2 (en) 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
EP3331569A1 (en) 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
WO2017030909A1 (en) 2015-08-14 2017-02-23 Allergan, Inc. Heavy chain only antibodies to pdgf
EP3998076A1 (en) 2015-09-17 2022-05-18 Histide AG Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
EP3906932A3 (en) 2015-09-17 2021-12-01 Histide AG Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
WO2017060397A1 (en) 2015-10-09 2017-04-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival time of subjects suffering from melanoma metastases
WO2017070460A1 (en) 2015-10-22 2017-04-27 Massachusetts Institute Of Technology Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
US20190330336A1 (en) 2015-11-19 2019-10-31 Sutro Biopharma, Inc. Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
PT3383920T (pt) 2015-11-30 2024-04-15 Univ California Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
SG11201804957VA (en) 2015-12-16 2018-07-30 Gritstone Oncology Inc Neoantigen identification, manufacture, and use
SG11201806419RA (en) 2016-01-27 2018-08-30 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
BR112018067525A2 (pt) 2016-02-26 2019-02-05 Centre Nat Rech Scient anticorpos tendo especificidade para o btla e seus usos
EP3423490A1 (en) 2016-03-01 2019-01-09 H. Hoffnabb-La Roche Ag Obinutuzumab and rituximab variants having reduced adcp
CN108698047B (zh) 2016-03-11 2022-04-01 豪夫迈·罗氏有限公司 电化学发光检测中的支链胺
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
EP3241845A1 (en) 2016-05-06 2017-11-08 MAB Discovery GmbH Humanized anti-il-1r3 antibodies
EP3472197A1 (en) 2016-06-15 2019-04-24 Sutro Biopharma, Inc. Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
EP3491022A1 (en) 2016-07-29 2019-06-05 Institut National de la Sante et de la Recherche Medicale (INSERM) Antibodies targeting tumor associated macrophages and uses thereof
EP3504239B1 (en) 2016-08-25 2024-05-29 F. Hoffmann-La Roche AG Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
WO2018049261A1 (en) 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
WO2018071597A1 (en) 2016-10-12 2018-04-19 Sutro Biopharma, Inc. Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
TWI778985B (zh) 2016-10-20 2022-10-01 法商賽諾菲公司 抗chikv抗體及其用途
EP3535295A1 (en) 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
US10316037B1 (en) 2016-11-04 2019-06-11 Yale University Compounds and methods for treating cancer
US12049511B2 (en) 2016-11-10 2024-07-30 Fortis Therapeutics, Inc. Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
JOP20190100A1 (ar) 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
WO2018091720A1 (en) 2016-11-21 2018-05-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the prophylactic treatment of metastases
CA3045323A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
EP3555620A1 (en) 2016-12-13 2019-10-23 H. Hoffnabb-La Roche Ag Method to determine the presence of a target antigen in a tumor sample
WO2018114772A1 (en) 2016-12-21 2018-06-28 F. Hoffmann-La Roche Ag Assay for determining antibody or ligand binding and function
JP6931058B2 (ja) 2016-12-21 2021-09-01 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗体のインビトロ糖鎖工学における酵素の再使用
MX2019006266A (es) 2016-12-21 2019-08-21 Hoffmann La Roche Glucomanipulacion in vitro de anticuerpos.
CN110088292A (zh) 2016-12-21 2019-08-02 豪夫迈·罗氏有限公司 用于体外糖工程化抗体的方法
CN110072553B (zh) 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
WO2018122053A1 (en) 2016-12-29 2018-07-05 F. Hoffmann-La Roche Ag Anti-angiopoietin-2 antibody formulation
WO2018156785A1 (en) 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
CN110392697A (zh) 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
JP7308150B2 (ja) 2017-03-16 2023-07-13 イナート・ファルマ・ソシエテ・アノニム 癌を処置するための組成物及び方法
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
EP3401332A1 (en) 2017-05-08 2018-11-14 MAB Discovery GmbH Anti-il-1r3 antibodies for use in inflammatory conditions
WO2018217940A2 (en) 2017-05-24 2018-11-29 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
US11464845B2 (en) 2017-07-21 2022-10-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neisseria meningitidis immunogenic compositions
US11174322B2 (en) 2017-07-24 2021-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies and peptides to treat HCMV related diseases
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
KR102670957B1 (ko) 2017-07-26 2024-05-31 포티 세븐, 인코포레이티드 항-sirp-알파 항체 및 관련 방법
EP3658584A1 (en) 2017-07-26 2020-06-03 H. Hoffnabb-La Roche Ag Combination therapy with a bet inhibitor, a bcl-2 inhibitor and an anti-cd20 antibody
KR20200051802A (ko) 2017-09-18 2020-05-13 서트로 바이오파마, 인크. 항-엽산 수용체 알파 항체 접합체 및 이의 용도
CA3074933A1 (en) 2017-09-21 2019-03-28 Imcheck Therapeutics Sas Antibodies having specificity for btn2 and uses thereof
AU2018348165A1 (en) 2017-10-10 2020-05-21 Gritstone Bio, Inc. Neoantigen identification using hotspots
EP3710482A4 (en) 2017-11-14 2021-08-18 University Of Virginia Patent Foundation COMPOSITIONS AND METHODS OF MANUFACTURING AND USING BISPECIFIC ANTIBODIES
IL274799B1 (en) 2017-11-22 2025-01-01 Gritstone Bio Inc Reducing epitope binding presentation for neoantigens
GB201719646D0 (en) 2017-11-27 2018-01-10 Bivictrix Therapeutics Ltd Therapy
CN111491951B (zh) 2017-12-22 2024-05-24 豪夫迈·罗氏有限公司 通过疏水相互作用色谱法耗尽轻链错配的抗体变体
MX2020007077A (es) 2018-01-04 2020-10-28 Iconic Therapeutics Inc Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
CA3084370A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
IL276383B2 (en) 2018-02-06 2024-01-01 Hoffmann La Roche Treatment of ophthalmological diseases
US11993658B2 (en) 2018-03-26 2024-05-28 Sutro Biopharma, Inc. Anti-BCMA antibodies and treatment methods
MX2020009991A (es) 2018-03-28 2020-10-14 Axon Neuroscience Se Metodos basados en anticuerpos para detectar y tratar la enfermedad de alzheimer.
WO2019195561A2 (en) 2018-04-06 2019-10-10 BioLegend, Inc. Anti-tetraspanin 33 agents and compositions and methods for making and using the same
CN113166218B (zh) 2018-04-11 2024-08-13 信立泰生物医药公司 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法
GB201807367D0 (en) 2018-05-04 2018-06-20 Univ Newcastle Biomarker
WO2019231326A1 (en) 2018-05-31 2019-12-05 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) Teipp neoantigens and uses thereof
US11377503B2 (en) 2018-06-18 2022-07-05 Innate Pharma Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
CN113614112A (zh) 2018-09-10 2021-11-05 莱顿教学医院 MuSK抑制
US20240043562A1 (en) 2018-09-10 2024-02-08 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) Musk activation
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
EP3856343A1 (en) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9 agents and compositions and methods for making and using the same
AU2019346598A1 (en) 2018-09-27 2021-04-29 Tizona Therapeutics Anti- HLA-G antibodies, compositions comprising anti- HLA-G antibodies and methods of using anti- HLA-G antibodies
GB201816554D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
GB201816553D0 (en) 2018-10-10 2018-11-28 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
KR102590359B1 (ko) 2018-10-29 2023-10-16 에프. 호프만-라 로슈 아게 항체 제형
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
EP3877413A1 (en) 2018-11-06 2021-09-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
US11827710B2 (en) 2019-02-11 2023-11-28 Zumutor Biologics Inc. Antibodies that bind to c-type lectin domain family 2 member d (CLEC2D)
MX2021011334A (es) 2019-03-20 2021-12-10 Imcheck Therapeutics Sas Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EP3947446A1 (en) 2019-03-25 2022-02-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment of taupathy disorders by targeting new tau species
JP2022531001A (ja) 2019-05-03 2022-07-05 セルジーン コーポレーション 抗ｂｃｍａ抗体コンジュゲート、そのコンジュゲートを含む組成物ならびにそのコンジュゲートの製造および使用方法
US20220362394A1 (en) 2019-05-03 2022-11-17 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
US20220242871A1 (en) 2019-06-10 2022-08-04 Sutro Biopharma, Inc. 5H-PYRROLO[3,2-d]PYRIMIDINE-2,4-DIAMINO COMPOUNDS AND ANTIBODY CONJUGATES THEREOF
EP3983410A1 (en) 2019-06-17 2022-04-20 Sutro Biopharma, Inc. 1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
EP4007775A1 (en) 2019-08-02 2022-06-08 Orega Biotech Novel il-17b antibodies
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
EP3825330A1 (en) 2019-11-19 2021-05-26 International-Drug-Development-Biotech Anti-cd117 antibodies and methods of use thereof
WO2021146383A1 (en) 2020-01-17 2021-07-22 BioLegend, Inc. Anti-tlr7 agents and compositions and methods for making and using the same
AU2021225962A1 (en) 2020-02-28 2022-10-20 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
WO2021175954A1 (en) 2020-03-04 2021-09-10 Imcheck Therapeutics Sas Antibodies having specificity for btnl8 and uses thereof
CN115843268A (zh) 2020-04-17 2023-03-24 纽约大学 治疗性MuSK抗体
EP4139340A1 (en) 2020-04-22 2023-03-01 Merck Sharp & Dohme LLC Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer
EP4142722A1 (en) 2020-04-30 2023-03-08 Bristol-Myers Squibb Company Methods of treating cytokine-related adverse events
CN115551553A (zh) 2020-05-12 2022-12-30 Inserm(法国国家健康医学研究院) 治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法
EP3915641A1 (en) 2020-05-27 2021-12-01 International-Drug-Development-Biotech Anti-cd5 antibodies and methods of use thereof
US20240148889A1 (en) 2020-06-11 2024-05-09 President And Fellows Of Harvard College Stabilized trioxacarcin antibody drug conjugates and uses thereof
BR112022026359A2 (pt) 2020-06-25 2023-01-17 Medimmune Ltd Prevenção de dano axonal usando anticorpo que se liga ao beta amiloide 1-42
MX2023001625A (es) 2020-08-07 2023-05-16 Fortis Therapeutics Inc Inmunoconjugados que se dirigen a cd46 y metodos de uso de los mismos.
IL301004A (en) 2020-09-04 2023-04-01 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
AU2020468491A1 (en) 2020-09-15 2023-04-27 Imperial College Innovations Limited Treatment of idiopathic pulmonary fibrosis
GB202016349D0 (en) 2020-10-15 2020-12-02 Imp College Innovations Ltd Proteome analysis in pulmonary hypertension
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
GB202017673D0 (en) 2020-11-09 2020-12-23 Imperial College Innovations Ltd Treatment of pulmonary arterial hypertensive
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
TW202308702A (zh) 2021-04-30 2023-03-01 美商西建公司 使用抗BCMA抗體藥物結合物(ADC)組合γ分泌酶抑制劑(GSI)之組合療法
EP4340876A1 (en) 2021-05-19 2024-03-27 Sutro Biopharma, Inc. Anti-folate receptor conjugate combination therapy with bevacizumab
TW202321277A (zh) 2021-07-27 2023-06-01 德商英麥提克生物技術股份有限公司 特異性結合ｃｔ４５之抗原結合蛋白
AU2022332285A1 (en) 2021-08-23 2024-02-15 Immunitas Therapeutics, Inc. Anti-cd161 antibodies and uses thereof
CN118176217A (zh) 2021-10-14 2024-06-11 徕特康(苏州)生物制药有限公司 新型抗体-细胞因子融合蛋白及其制备方法和用途
TW202330613A (zh) 2021-11-12 2023-08-01 美商建南德克公司 使用整聯蛋白β７拮抗劑治療克隆氏病之方法
WO2023096904A2 (en) 2021-11-24 2023-06-01 President And Fellows Of Harvard College C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof
AU2022402850A1 (en) 2021-12-01 2024-06-06 Sutro Biopharma, Inc. Anti-folate receptor conjugate cancer therapy
WO2023170239A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Methods and tools for conjugation to antibodies
IL315308A (en) 2022-03-09 2024-10-01 Astrazeneca Ab Binding molecules against frα
AU2023229967A1 (en) 2022-03-11 2024-08-08 Astrazeneca Ab A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
WO2023178086A1 (en) 2022-03-15 2023-09-21 Salubris Biotherapeutics, Inc. Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein
WO2024006563A1 (en) 2022-07-01 2024-01-04 Sutro Biopharma, Inc. Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
WO2024044780A1 (en) 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
WO2024062074A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use
WO2024098023A2 (en) 2022-11-04 2024-05-10 Sutro Biopharma, Inc. Interferon alpha polypeptides and conjugates
NL2033789B1 (en) 2022-12-21 2024-06-27 Academisch Ziekenhuis Leiden Novel C1q antibodies and uses thereof
WO2024136640A1 (en) 2022-12-21 2024-06-27 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) C1q antibodies and uses thereof
WO2024170660A1 (en) 2023-02-16 2024-08-22 Astrazeneca Ab Combination therapies for treatment of cancer with therapeutic binding molecules
WO2025006737A1 (en) 2023-06-30 2025-01-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025021968A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Antigen binding proteins against mageb2

Also Published As

Publication number Publication date
HK63094A (en) 1994-07-01
FI97303B (fi) 1996-08-15
EP0315062A3 (en) 1990-03-28
NO178234C (no) 1996-02-14
DK174339B1 (da) 2002-12-16
FI884907A (fi) 1989-04-28
NZ226695A (en) 1991-12-23
IE61733B1 (en) 1994-11-30
IE883244L (en) 1989-04-27
AU2444688A (en) 1989-04-27
US5204244A (en) 1993-04-20
FI884907A0 (fi) 1988-10-24
EP0315062A2 (en) 1989-05-10
CY1778A (en) 1995-10-20
ES2061598T3 (es) 1994-12-16
AU607013B2 (en) 1991-02-21
IL88149A0 (en) 1989-06-30
NO178234B (no) 1995-11-06
JPH02477A (ja) 1990-01-05
DE3887085D1 (de) 1994-02-24
JP2624314B2 (ja) 1997-06-25
PT88858B (pt) 1993-01-29
DE3887085T2 (de) 1994-05-19
EP0315062B1 (en) 1994-01-12
DK594588D0 (da) 1988-10-26
IL88149A (en) 1993-06-10
CN1033290A (zh) 1989-06-07
FI97303C (fi) 1996-11-25
NO884771L (no) 1989-04-28
CA1334177C (en) 1995-01-31
DK594588A (da) 1989-04-28

Similar Documents

Publication Publication Date Title
NO884771L (no) Fremgangsmaate for fremstilling av et kimerisk antistoffmolekyl.
NO885327D0 (no) Kjemiske preparater.
DK40788D0 (da) Kemiske forbindelser
DE3883899D1 (de) Geänderte antikörper.
NO873164D0 (no) Muse-humane kimaere antistoffer.
DK90788D0 (da) Kemiske forbindelser
NO884058D0 (no) Fremgangsmaate for fremstilling av cefemforbindelser.
NO870770L (no) FremgangsmŸte for fremstilling av monoklonale antistoffer.
NO880262D0 (no) Fremgangsmaate for fremstilling av b avermectiner.
NO885359D0 (no) Fremgangsmaate for fremstilling av sprengstoff.
NO872174L (no) Fremgangsmaate for fremstilling av polypeptidpreparater med oekt biologisk tilgjengelighet.
PT86960A (pt) Process for the preparation of immunoglobulin conjugates
NO170022C (no) Fremgangsmaate for fremstilling av sialocylglycerolipider.
NO882730L (no) Fremgangsmaate for fremstilling av aminocyklopentyletere.
NO885200L (no) Fremgangsmaate for fremstilling av pro-legemidler.
NO851386L (no) Fremgangsmaate for fremstilling av antigen.
NO882257L (no) Fremgangsmaate for fremstilling av et glidelaasbaand.
NO880834D0 (no) Fremgangsmaate for fremstilling av heterocyclyl-2-propyn-1-aminer.
NO891020D0 (no) Fremgangsmaate for fremstilling av buten-1.
NO913089D0 (no) Fremgangsmaate for fremstilling av tetrazolforbindelser.
FI874368A (fi) Anordning foer rengoerning av skor.
NO880844L (no) Fremgangsmaate for fremstilling av cytotoksiner.
NO169281C (no) Fremgangsmaate for fremstilling av heksanitrostilben.
ATE94171T1 (de) Geaenderte antikoerper.
DK500987D0 (da) Kemiske forbindelser

Legal Events

Date Code Title Description
MK1K Patent expired